BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 12115382)

  • 1. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
    Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
    Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
    Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic oophorectomy: a morphologic and immunohistochemical study.
    Schlosshauer PW; Cohen CJ; Penault-Llorca F; Miranda CR; Bignon YJ; Dauplat J; Deligdisch L
    Cancer; 2003 Dec; 98(12):2599-606. PubMed ID: 14669279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic imbalance and onco-protein expression of ovarian endometrioid adenocarcinoma arisen in an endometriotic cyst.
    Noack F; Schmidt H; Buchweitz O; Malik E; Horny HP
    Anticancer Res; 2004; 24(1):151-4. PubMed ID: 15015590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
    Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
    Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
    Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
    Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
    Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
    Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDC42-positive macrophages may prevent malignant transformation of ovarian endometriosis.
    Canet B; Pons C; Espinosa I; Prat J
    Hum Pathol; 2012 May; 43(5):720-5. PubMed ID: 21944080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical discussion of the relationship between endometriosis and epithelial ovarian cancer].
    Zhang Y; Huang H; Lian L
    Zhonghua Fu Chan Ke Za Zhi; 1999 Sep; 34(9):544-6. PubMed ID: 11360640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [bcl-2 and p53 protein expressions in the malignant transformation of ovarian endometriosis].
    Qian J; Shi Y
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):403-5. PubMed ID: 11810773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
    Kuwata T; Kitagawa M; Takemura T; Hirokawa K
    Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype.
    Mandai M; Matsumura N; Baba T; Yamaguchi K; Hamanishi J; Konishi I
    Cancer Lett; 2011 Nov; 310(2):129-33. PubMed ID: 21802200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.
    Cao SN; Chang KH; Luthra R; Liu J
    Mod Pathol; 2003 Oct; 16(10):1048-52. PubMed ID: 14559989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
    Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
    Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
    APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type.
    Cuff J; Longacre TA
    Am J Surg Pathol; 2012 May; 36(5):688-95. PubMed ID: 22498820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological classification of ovarian cancer.
    Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
    Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress.
    Yamaguchi K; Mandai M; Toyokuni S; Hamanishi J; Higuchi T; Takakura K; Fujii S
    Clin Cancer Res; 2008 Jan; 14(1):32-40. PubMed ID: 18172249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.